Trial Profile

An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI 836880 (Primary) ; Ezabenlimab (Primary)
Indications Brain cancer; Glioblastoma; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Skin cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Boehringer Ingelheim

02 Oct 2024 Status changed from active, no longer recruiting to completed.
04 Sep 2024 Planned End Date changed from 1 Nov 2024 to 12 Sep 2024.
21 Aug 2024 Planned primary completion date changed from 6 Aug 2024 to 28 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com